University of Pennsylvania

ScholarlyCommons
Departmental Papers (Dental)

Penn Dental Medicine

2000

Fusion Between Retinal Rod Outer Segment Membranes and
Model Membranes: Functional Assays and Role for Peripherin/rds
Kathleen Boesze-Battaglia
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/dental_papers
Part of the Dentistry Commons

Recommended Citation
Boesze-Battaglia, K. (2000). Fusion Between Retinal Rod Outer Segment Membranes and Model
Membranes: Functional Assays and Role for Peripherin/rds. Methods in Enzymology, 316 65-86. Retrieved
from https://repository.upenn.edu/dental_papers/244

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/dental_papers/244
For more information, please contact repository@pobox.upenn.edu.

Fusion Between Retinal Rod Outer Segment Membranes and Model Membranes:
Functional Assays and Role for Peripherin/rds
Abstract
Membrane fusion is defined as the consolidation of two membrane bilayers and a subsequent mixing of
the two previously separated aqueous compartments. Membrane fusion processes are mediated and
regulated by a growing family of soluble and integral membrane proteins termed fusion proteins.1,2
Fusion proteins share structural and functional properties and aid in the thermodynamically unfavorable
fusion event by promoting hydrophobic interactions that favor fusion.1–3
Within retinal photoreceptor rod cells membrane fusion is a component step of at least three essential
cellular processes. Fusion is necessary for the delivery of proteins and lipids in vesicles from the rod inner
segment (site of synthesis) to the rod outer segment (ROS). Two additional fusion processes preserve the
unique architecture of the outer segment by maintaining the outer segment at a constant length. The
coordinated processes of disk morphogenesis and compensatory disk shedding4 require the fusion of
two opposing membranes: the fusion of two outgrowing inside-out disk rims for morphogenesis,5 and
disk–plasma membrane fusion for disk packet formation.6 Fusion during disk packet formation is
documented in microscopy studies in which an analysis of dye penetration into distinct regions of the
ROS found that large molecules do not enter the narrow bands of the dye-stained region of the ROS,
suggesting a fusion of the plasma membrane with the disk membranes.7,8 This fusion is mediated by a
fusion protein unique to photoreceptors: peripherin/rds. In this chapter we describe the protocols used in
photoreceptor cell-free fusion assays and the characterization of peripherin/rds as a rod cell-specific
fusion protein
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Introduction
Membrane fusion is defined as the consolidation of two membrane bilayers and a
subsequent mixing of the two previously separated aqueous compartments. Membrane
fusion processes are mediated and regulated by a growing family of soluble and integral
membrane proteins termed fusion proteins.1,2 Fusion proteins share structural and functional
properties and aid in the thermodynamically unfavorable fusion event by promoting
hydrophobic interactions that favor fusion.1–3

Author Manuscript

Within retinal photoreceptor rod cells membrane fusion is a component step of at least three
essential cellular processes. Fusion is necessary for the delivery of proteins and lipids in
vesicles from the rod inner segment (site of synthesis) to the rod outer segment (ROS). Two
additional fusion processes preserve the unique architecture of the outer segment by
maintaining the outer segment at a constant length. The coordinated processes of disk
morphogenesis and compensatory disk shedding4 require the fusion of two opposing
membranes: the fusion of two outgrowing inside-out disk rims for morphogenesis,5 and
disk–plasma membrane fusion for disk packet formation.6 Fusion during disk packet
formation is documented in microscopy studies in which an analysis of dye penetration into
distinct regions of the ROS found that large molecules do not enter the narrow bands of the
dye-stained region of the ROS, suggesting a fusion of the plasma membrane with the disk
membranes.7,8 This fusion is mediated by a fusion protein unique to photoreceptors:
peripherin/rds. In this chapter we describe the protocols used in photoreceptor cell-free
fusion assays and the characterization of peripherin/rds as a rod cell-specific fusion
protein.6,9–13

Author Manuscript

General Principles Involved in Design of Fusion Assays
Membrane fusion must satisfy two criteria: (1) the merger of two membrane bilayers and (2)
the subsequent mixing of the aqueous contents.14 To characterize the molecular mechanism
of fusion, it is necessary to evaluate the two phenomena separately by distinct albeit
complementary techniques. In biological systems, the measurement of aqueous contents
mixing is often difficult or impossible to achieve and thus is often inferred from the
detection of lipid mixing. Unfortunately, the formation of a fusion pore independent of
aqueous contents mixing (i.e., hemifusion), can be misinterpreted as fusion.15 The careful
design and rigorous interpretation of control experiments avoid such misinterpretations.
Aqueous contents mixing in some biological systems is now detectable with the
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development of molecular genetics techniques that rely on the cytoplasmic activation of
reporter genes on fusion of two distinct cell populations.16 Fusion processes are measured in
vitro by a variety of techniques described elsewhere.17,18
The most sensitive and reliable measurements of the kinetics of a fusion process require
biophysical techniques,19 the most well characterized of which is fluorescence spectroscopy.
Fluorescence-based biological fusion assays are broadly divided into two categories: probe
dilution20 and resonance energy transfer,21 both of which measure the mixing of the lipids
within the membranes. Both of these techniques have been utilized in the design of
photoreceptor specific cell-free fusion assays.

Rod Outer Segment Membrane Fusion
Author Manuscript

In practice, lipid mixing is measured by the incorporation of a fluorescent probe into the
membrane bilayer and a change in fluorescence emission, accessed either through resonance
energy transfer pairs, or via a release of self-quenching, on fusion of the labeled membrane
with a suitable target membrane. In photoreceptors, the fusion assay used most often is
based on a relief of octadecylrhodamine B chloride (R18) self-quenching as two membrane
bilayers mix. When the R18-labeled membrane fuses with unlabeled target membrane, the
lipid-like probe is effectively diluted by its subsequent lateral diffusion within the target
membrane. Probe dilution is detected as a progressive linear increase in fluorescence
intensity, which is proportional to the extent of fusion.21 This technique allows kinetic and
quantitative measurements of fusion between labeled membranes and both artificial and
biological membranes.19–21 The typical protocol for R18 labeling of bovine ROS plasma
membrane and ensuing fusion follows.

Author Manuscript

Preparation and Labeling of Rod Outer Segment Plasma Membrane
Materials
Purified ROS plasma membrane vesicles
Octadecylrhodamine B chloride (R18; Molecular Probes, Eugene, OR)
Sephadex G-75 (Pharmacia, Piscataway, NJ)
Column buffer: 100 mM NaCl, 10 mM glycine, 0.1 mM EDTA, pH 7.5
Calcium chelating buffer: 5 mM HEPES, 1 mM EDTA, pH 7.4

Author Manuscript

ROS disks and plasma membranes are isolated from either fresh or frozen bovine retinas.22
The plasma membrane vesicles are purified free from ROS disk membranes by binding to
ricin120–agarose (Sigma, St. Louis, MO) and separated by continuous sucrose density
gradient centrifugation.22 The ROS plasma membrane bound to ricin–agarose is recovered
as a pellet in the gradient. The plasma membrane is eluted from the ricin–agarose in a
Pasteur pipette column with 1 M galactose in 0.1 M sodium borate, pH 8.0. The resulting
plasma membrane vesicles are washed free of galactose (spin at 50,000 rpm for 40 min at
10°) and resuspended in calcium chelating buffer.23 The phospholipid content of the
membrane is determined24,25 and the final concentration adjusted to 2.0 mM phosphate.
ROS plasma membrane vesicles must be labeled and used within a 24-hr period; otherwise
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vesicles become leaky and give spurious results. Both the preparation and labeling of the
ROS plasma membrane are performed under dim red light.
R18 Labeling of Rod Outer Segment Plasma Membrane

Author Manuscript

The freshly isolated ROS plasma membrane vesicles are labeled with R18.6 A stock solution
of R18 (10 mg/ml) is prepared in chloroform–methanol (1:1, v/v) and stored at −20°. An
aliquot of this solution is removed, dried under a stream of nitrogen, and reconstituted in a
minimal volume of ethanol. R18 is incorporated into the ROS plasma membrane at selfquenching concentrations, equivalent to approximately 5 mol% relative to the phospholipid
content of the ROS plasma membrane. Typically, a 2-ml suspension of ROS plasma
membrane (rhodopsin concentration, 1 mg/ml) is added to 10 μl of 10 nmol of R18, in
ethanol, under vigorous vortexing. Since the final incubation volume is 2 ml, the final
ethanol concentration is less than 1% (v/v). The mixture is rocked gently at room
temperature for 30–60 min in the dark.6

Author Manuscript

The unincorporated probe is removed by chromatography on a Sephadex G-75 column (total
volume of the column, 3–4 ml). The unincorporated R18 adsorbs to the top of the column,
and the R18-labeled plasma membrane is recovered in the void volume and identified by
absorbance at 214 nm. Free probe can also be removed with bovine serum albumin,11
followed by sucrose density gradient centrifugation. In addition to being more time
consuming, the bovine serum albumin (BSA) procedure may also remove membrane lipids
and alter bilayer properties. For the remainder of this chapter R18-labeled plasma membrane
is abbreviated as R18–PM. To quantitate the incorporation of R18 into the plasma membrane,
the labeled vesicles are extracted with chloroform–methanol (2:l).26 The fluorescence
intensity of an aliquot of the extract is measured and compared with the intensity of known
amounts of R18 in chloroform, which increase linearly up to concentrations of 1 nmol/ml.27
Preparation of Target Membranes
The accurate measurement of membrane fusion processes by relief of self-quenching
requires that the concentration of target membrane be at least 30- to 100-fold greater than
that of the R18-labeled species.28 In our experiments a surface area ratio between R18–PM
and target membranes of 1:50 or 1:100 yields satisfactory results, although the ratio of
labeled membrane to unlabeled membrane should be optimized for each system.28 R18–PM
fuse with a variety of target membranes including ROS disk membranes, disk rim-specific
vesicles, and disk lipid recombinant vesicles containing peripherin/rds. The preparation of
these target vesicles is described below.

Author Manuscript

Disk Membranes: Disk membranes are routinely isolated during the preparation of plasma
membrane from a continuous sucrose density gradient at 30% sucrose.22 In our experience,
50 frozen bovine retinas routinely yield 20–25 mg of disk membrane rhodopsin. The disk
membranes are washed free of sucrose and resuspended in calcium chelating buffer23 to a
rhodopsin concentration of 2.5 mg/ml for phosphate determination and diluted with
chelating buffer to a final phosphate concentration of 1 mM for fusion assays.

Methods Enzymol. Author manuscript; available in PMC 2016 January 29.
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Disk Rim-Specific Vesicles: Rim-specific vesicles have a protein content that closely
mimicks the protein content of the disk rim region, i.e., enriched in peripherin/rds,29,30
rom-1,31 and the rim–ABC protein,32 with negligible levels of rhodopsin. These vesicles are
prepared from disk membranes isolated as described in the preceding section. The disk
membranes are solubilized with octylglucoside (OG) and the solubilized mixture subjected
to concanavalin A affinity chromatography.33,34 The unbound fraction from the
concanavalin A column9 contains total disk lipids and the peripherin/rds and rom-1, which
do not bind to the column. This unbound fraction is collected and concentrated to a final
volume of 5–8 ml, using an Amicon (Danvers, MA) concentrator (YM10 filter). Disk rimspecific vesicles form spontaneously after the removal of OG by dialysis for 24–48 hr
against 1 M NaCl, 10 mM HEPES, pH 7.4, with two changes of buffer. The rim-specific
vesicles are not used for fusion unless the residual OG concentration (determined as
described35) is less than 0.05 mol% relative to phospholipid. If the OG concentration is
higher, the vesicles are dialyzed for an additional 24 hr in the presence of SM-2 BioBeads
(Bio-Rad, Hercules, CA). After dialysis, the vesicles are subject to five freeze–thaw cycles
[liquid nitrogen (freeze)/room temperature (thaw)]. The volume of vesicles is adjusted with
calcium chelating buffer to a final phospholipid concentration of 1 mM.

Author Manuscript

Peripherin/rds Recombinants: Peripherin/rds is purified from bovine retinas by a
combination of concanavalin A affinity chromatography and chromatofocusing techniques.9
Nonphosphorylated peripherin/rds is isolated from the chromatofocusing column at its pI of
4.7, and phosphorylated peripherin/rds at a pI of 4.21. Peripherin/rds and
phosphoperipherin/rds recombinants are prepared by detergent dialysis.36 In the preparation
of peripherin/rds recombinants, the purified protein is recombined with vesicles prepared
from extracted disk membrane lipids.12 Since retinal has been shown to induce lipidmediated fusion in photoreceptors, we reduce the retinal Schiff-base linkage with
NaCNBH3,37 thereby eliminating any retinal-induced effects on fusion. To prepare disk
lipid small unilamellar vesicles (SUVs) for recombination, freshly prepared 2 M NaCNBH3
in 1 M acetic acid is added to freshly isolated disk membranes in a 2:1 (v/v) ratio in the dark
and allowed to sit at room temperature for 45 min. The treated disk membranes are washed
and resuspended in 10 mM HEPES, pH 7.4, and extracted with 2:1 chloroform–methanol.26
The extracted lipids are dried under a stream of nitrogen, lyophilized overnight, and
resuspended in 10 mM HEPES, pH 7.4. SUVs are prepared from the liposomes.38 If
necessary, the amount of residual retinal(ol) can be quantitated by high-performance liquid
chromatography (HPLC).39

Author Manuscript

The disk lipid SUVs are recombined with purified peripherin/rds, isolated by
chromatofocusing. The peripherin/rds-containing fractions are combined and the pH
adjusted to 7.0 with 0.1 M imidazole, pH 8.0. The sample is concentrated to one-tenth its
original volume with a Centricon 30 filter device (30,000 MW cutoff filter). The
ultrafiltration device is centrifuged at 7500g at 4°, time variable, using a fixed-angle rotor.
The concentrated purified peripherin/rds in 20–30 mM OG is added to disk lipid SUVs with
vigorous vortexing and the mixture placed in an ice bath for 1 hr. The resulting solution
should be cloudy, indicating that the OG concentration in the recombinant is below the
critical micelle concentration of the detergent. Routinely, a ratio of 1 mol of peripherin/rds
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to 100–300 mol of phospholipid is used. The recombinant is then dialyzed against 10 mM
HEPES, 0.5 M NaCl, pH 7.4, for 24–48 hr, with three changes of buffer, with the final
buffer change containing SM-2 BioBeads (Bio-Rad). Under these experimental conditions,
less than 0.05% OG remains associated with the recombinants. The recombinant-containing
peripherin/rds in the disk lipid vesicles is purified on a continuous 10–40% (w/w) sucrose
density gradient, spun at 25,000 rpm for 8 hr at 4°. The recombinant is routinely isolated as
a single band at approximately 20–30% sucrose, depending on the final phospholipid/protein
ratio. Peripherin/rds in the recombinant is oriented asymmetrically, such that all of the
peripherin/rds molecules are inserted with their extra-diskal side out. This orientation is
confirmed by immunofluorescence with anti-peripherin/rds monoclonal antibody 2B6 to the
C terminus (generously provided by R. Molday29) or by trypsinolysis.9,10 The peripherin/rds
recombinants are subject to five freeze–thaw cycles: rapid freezing in liquid nitrogen
followed by thawing at room temperature to form large unilamellar vesicles called
peripherin/rds LUVs. Disk lipid vesicles containing no peripherin/rds or rhodopsin
recombinants, which do not to fuse with R18– PM, are used as controls.9,12,36
R18 Fusion Assay

Author Manuscript

Fusion between R18–PM and target membranes is detected as an increase in fluorescence
intensity at 586 nm on dilution of R18 throughout the target membrane. In designing these
assays it is essential that the amount of lipid in the R18–PM be 50-fold lower than the
amount of phospholipid in the target membranes. Therefore, we routinely adjust the
phospholipid concentration of the target membrane to 1 mM. The assays are performed in a
total volume of either 3 or 1 ml. The calcium concentration of the target membrane is
adjusted by the addition of CaCl2 to the cuvette prior to or simultaneously with the initiation
of fusion. Fluorescence and light scattering are monitored with λex 560 nm and λem 586 nm
on a Perkin-Elmer (Norwalk, CT) LS50 B spectrofluorimeter or equivalent.
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The target membranes are equilibrated to the appropriate temperature while stirring in a
thermostatted cuvette turret. Fusion is initiated by the addition of 50 μl of R18–PM to this
suspension of target membrane. The change in R18 fluorescence is monitored continuously
and increases linearly as the probe dilutes into the target membrane (see Fig. 1). The
increase in observed fluorescence intensity is proportional to the membrane fusion.6,21 The
fluorescence intensity of the target membrane without addition of plasma membrane is taken
as baseline fluorescence and is equal to 0% fusion. Fluorescence at 100%, equal to 100%
fusion, is determined by the addition of 100 μl of 10% Triton X-100 to the membrane
mixture. Triton X-100 does not interfere with rhodamine fluorescence and the only
correction factor required is that due to dilution. The initial rate of fusion (IRF) is
determined as the percent increase in fluorescence intensity as a function of time21 as shown
in Eq. (1).

(1)

where slope R18 is equal to the linear change in R18 fluorescence over time, F0 is the
fluorescence intensity at baseline (i.e., in the absence of labeled R18–PM), and Ff is the
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fluorescence intensity on the addition of Triton X-100. If a lag time is observed the slope
R18 is determined only after the lag phase.
Analysis of Fluorescence Data
The parameters obtained from the fluorescence data used to characterize the fusion process
are as follows: (1) the initial rate of fusion, determined from the slope of the fluorescence
increase (Figs. 1 and 2), (2) the extent of fusion, determined on an overnight incubation
between R18–PM and target membranes, and (3), in some cases, the lag time prior to the
initiation of fusion (Fig. 2).
Characteristics of Fusion between R18-Labeled Plasma Membrane and Target Membranes

Author Manuscript

Fusion between R18–PM and the target membranes share common characteristics: fusion
increases linearly over time, requires nanomolar levels of calcium, and is completely
inhibited by the addition of 100 μl of 1 M EGTA. Fusion is temperature dependent, with the
highest initial rates at 37° and almost no detectable fusion above 45° or below 30°.

Author Manuscript

Disk Membranes: A representative tracing of the increase in fluorescence intensity
observed upon the fusion of R18–PM with isolated disk membranes6 is shown in Fig. 1.
Fusion is initiated by the simultaneous addition (Fig. 1, 1a) of R18–PM and calcium to a
suspension of disk membranes at 37°. Maximal fusion is determined by the addition of
Triton X-100 (Fig. 1, 1b). The slope of the fluorescence increase is used to calculate the
initial rate of fusion. The fusion between disk membranes and R18–PM can be inhibited by
modifications of endogenous peripherin/rds, such as trypsinolysis of the disk
membranes,9,10 the addition of anti-peripherin monoclonal antibody 2B6,9 or the addition of
low concentrations of the peptide PP-5,10 corresponding to amino acids 311 to 325 of
bovine peripherin/rds.
Disk Rim-Specific Vesicles or Peripherin/rds Recombinants: When R18–PM fuse with
either rim-specific vesicles or peripherin/rds recombinants, a qualitatively different
fluorescence pattern is observed as shown in Fig 2. When fusion of R18–PM with
peripherin/rds recombinants is measured at 37° a lag phase lasting 120 sec occurs, during
which time little or no fusion is observed.10 This lag time increases to almost 300 sec when
the temperature is lowered to 30°. Similar results are obtained with rim-specific vesicles,
with the exception that the lag phase is shorter in duration; for example, at 37°, the lag phase
is 60–100 sec. A comparison of these parameters is given in Table I.

Author Manuscript

To ensure that the observed lag phase results from fusion-related events, both the
temperature dependence and the effect of proteolysis or phospholipase treatment on fusion
should be analyzed. A lag in the onset of fusion should increase when the temperature is
lowered. If the fusion is protein mediated, the lag phase would also change in duration on
proteolysis of the proposed fusion protein. Conversely, if the fusion is lipid mediated then
any alteration in lipid properties after phospholipase treatment would affect a true lag phase.
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The use of endogenous probes for the measurement of membrane fusion requires that a
number of critical factors be considered and controls designed to account for specious
results. Under some experimental conditions, a spontaneous transfer of R18 between
membranes can occur in the absence of membrane merging and fusion.40 Such transfer has
not been seen to any appreciable extent with R18–PM, when these membranes are incubated
with phosphatidylcholine LUVs.6 In our experience, spontaneous transfer of R18 from
plasma membrane vesicles to phosphatidylcholine SUVs or LUVs is indicative of permeable
vesicles due to prolonged storage (longer than 24 hr).

Author Manuscript

Fusion should also be confirmed by alternative techniques, i.e., sucrose density gradient
centrifugation (allows the separation of fused from unfused species11,12) or microscopy.17,18
Alternatively, the addition of high concentrations of unlabeled plasma membrane should
inhibit R18 dequenching, indicating that the increase in fluorescence was due to the merger
of two membranes. Conversely, binding of R18-labeled membranes to the target membrane
should result in no dequenching or in a nonlinear change in R18 fluorescence. Investigators
are strongly encouraged, when possible, to compare different fusion assays in the same
system and to characterize known fusion properties of the membranes (i.e., specific
inhibitors, temperature dependence, cation dependence, membrane specificity).

Characterization of Molecular Basis of Peripherin/rds-Mediated Fusion

Author Manuscript

Peripherin/rds is the first rod cell-specific fusion protein to be identified. Fusion is mediated
through at least one region of peripherin/rds, from residues 311 to 325. A peptide analog to
this region, called PP-5, promotes membrane adhesion and membrane destabilization,9,10,13
two prerequisite steps for fusion.41

Author Manuscript

An initial strategy in the identification of a candidate fusion protein and subsequent
characterization of a fusogenic region within such a protein relies on proteolysis studies.
Trypsinolysis of peripherin/rds led to the identification of a fusion-promoting region.9,10
The target membranes are incubated with trypsin (final concentration, 0.2 μg/ml) for 30 min
in the dark at 37°. The reaction is stopped by the addition of trypsin inhibitor (final
concentration, 0.4 mg/ml), and the samples are washed in 10 mM HEPES, pH 7.2, and
centrifuged at 60,000 rpm for 40 min. The pellet is resuspended in 10 mM HEPES, pH 7.2,
for the fusion assay; the supernatant containing the tryptic fragments is reserved on ice.
Trypsinolysis of disk membranes and peripherin/rds recombinants under these conditions
results in the cleavage of a 12.5-kDa band immunoreactive with anti-peripherin/rds antibody
2B6, which was found to correspond to the C terminus of peripherin/rds. Cleavage of this
peptide fragment inhibited fusion of disks and peripherin/rds recombinants with R18–PM.10
Fusion activity is restored with the subsequent addition of the tryptic fragments at a ratio
equal to that in the native membrane.10 The size of the tryptic fragments is determined by
gradient gel electrophoresis42 and/or HPLC.43 Such experiments provide evidence that the
tryptic fragments contain a fusion-promoting region of peripherin/rds that retained
biological activity, as determined on the basis of the restoration of fusion activity, and led to
the synthesis of overlapping C-terminal peptides (Table II).

Methods Enzymol. Author manuscript; available in PMC 2016 January 29.

Boesze-Battaglia

Page 8

Peptide-Induced Aqueous Contents Mixing as Measure of Fusion

Author Manuscript

The fusion-promoting activity of tryptic fragments and synthetic peptides is evaluated
directly in an assay measuring the mixing of the aqueous contents of model membranes.
This approach allows the investigator to determine if a peptide satisfies both criteria for
fusion, i.e., membrane lipid and aqueous contents mixing. A fluorescence-based contents
mixing assay using 8-aminonaphthalene-1,3,6-trisulfonic acid and p-xylene bispyridinium
bromide (ANTS and DPX, respectively) has been chosen since these membranes are not
biologically active. This assay is based on the principle that the fluorescence of one probe,
ANTS, is quenched by a second probe, DPX; such probes are called quenching pairs.44 The
two fluorophores are encapsulated separately into two different populations of vesicles. On
fusion and contents mixing a collisional quenching of the ANTS occurs and is detected as a
decrease in fluorescence.44,45
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Materials
ANTS: 8-Aminonaphthalene-l,3,6-trisulfonic acid, disodium salt (Molecular Probes);
store in dark
DPX: p-Xylene bispyridium bromide (Molecular Probes); store in dark
PS: Phosphatidylserine (bovine brain; Avanti Polar Lipids, Alabaster, AL)
N-Methyl-DOPE: N-Monomethyldioleoylphosphatidylethanolamine (Avanti Polar
Lipids)
ANTS buffer: 10 mM Glycine, 45 mM NaCl, 25 mM ANTS, pH 9.5
DPX buffer: 10 mM Glycine, 90 mM DPX, pH 9.5

Author Manuscript

Preparation of ANTS- or DPX-Containing Vesicles
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Large unilamellar vesicles (LUVs) encapsulating either ANTS or DPX are prepared from 95
mol% N-methyl-DOPE and 5 mol% PS (bovine brain).45,46 The dried lipids are resuspended
in buffer containing either ANTS or DPX, subjected to five freeze–thaw cycles in liquid
nitrogen, and extruded through a polycarbonate filter (Poretics, Pleasanton, CA; 467 mm,
pore size 0.1 μm), using a Nuclepore (Pleasanton, CA) 47-mm in-line filter holder.45
Encapsulated fluorescent probe is separated from unincorporated probe on a Sephadex G-50
column eluted with 100 mM NaCl, 10 mM glycine, and 0.1 mM EDTA, pH 9.5. The vesicles
containing the encapsulated probe elute with the void volume. Both the ANTS-containing
and the DPX-containing vesicles are resuspended in 10 mM glycine, pH 9.5, to a final 1 mM
phosphate concentration. The pH of the solutions must be accurate since N-monomethylDOPE will form nonbilayer structures below pH 8.0, resulting in vesicle aggregation.
ANTS-DPX Contents Mixing Assay
Fluorescence intensity is monitored at λex 380 nm and λem 510 nm. In a 3-ml fusion reaction
mixture, the thermostatted cuvette contains 30 μl of ANTS-containing vesicles, 270 μ1 of
DPX-containing vesicles, and 2.7 ml of column buffer (100 mM NaCl, 10 mM glycine, and
0.1 mM EDTA, pH 9.5). Fusion is initiated by lowering the pH of the fusion mixture from
9.5 to 4.5 (Fig. 3a) by the addition of 2 M sodium acetate–acetic acid (25–50 μl). Fusion is
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measured as a decrease in fluorescence intensity as the aqueous contents are mixed and an
ANTS–DPX complex is formed. Baseline fluorescence is the intensity obtained with the
shutters closed. The 100% fluorescence level is the initial fluorescence intensity before
lowering the pH. The IRF between ANTS- and DPX-containing vesicles is calculated as
shown in Eq. (2)47:

(2)

where slopeANTS/DPX is equal to the linear change in ANTS fluorescence over time, F0 is
the fluorescence intensity prior to the initiation of fusion with acetic acid and Ff is the
fluorescence intensity with the shutters closed.

Author Manuscript

Effect of Peripherin/rds Peptides on ANTS–DPX Fusion
To determine if the various synthetic peptides to the C terminus of peripherin/rds are
fusogenic, the ANTS–DPX fusion mixture is preincubated with the peptide at the desired
temperature prior to the initiation of fusion. Routinely, the effect of a single peptide
concentration on fusion is studied within a temperature range of 28 to 42°. The peptide
concentrations used are in the millimolar to nanomolar range. Such studies, while necessary
to describe a mechanistic pathway, should be performed to complement the fusion assays
described above.
Pitfalls

Author Manuscript

ANTS–DPX Fusion: Transient perturbations, analogous to hemifusion, can be
distinguished from fusion by ANTS–DPX leakage assays.48 The ANTS–DPX assay cannot
be used to measure aqueous contents mixing of SUVs because ANTS binds excessively to
such vesicles.49
Synthetic Peptides: To confirm the specificity of a peptide-induced fusion, a scrambled
peptide (same amino acids in a different sequence), a fusogenic peptide from a different
system, e.g., a viral fusion peptide, or a nonspecific peptide at high concentration should be
tested. The fusogenic peptide should produce an effect at physiologically relevant peptide
concentrations. Peptide-induced fusion in a model membrane system should affect fusion in
the biological cell-free assay system. In photoreceptors, PP-5 inhibits fusion between disk
and R18–PM when added in a 1:1 ratio with peripherin/rds.10 The secondary structure of the
peptide should be evaluated in the fusion mixture and an effort made to denature this
structure and show that the denatured species is unable to induce fusion.

Author Manuscript

Peripherin/rds Mutagenesis
Fusion-promoting region(s) of peripherin/rds can also be identified by mutagenesis.
Peripherin/rds mutagenesis studies require a viable cell expression system in which the
fusion competence of the cells or of the proteins harvested from the cells can be determined.
The protocol for the determination of this fusion competency in Madin–Darby canine kidney
(MDCK) cells is given below. A similar strategy can potentially be employed to characterize
other cell expression systems.
Methods Enzymol. Author manuscript; available in PMC 2016 January 29.
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Establishment of Fusion Competency of MDCK Cells Expressing Human Peripherin/rds
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MDCK strain II cells stably transfected with human peripherin/rds with an Xpress Nterminal tag50 have been generously provided by R. Kim. The peripherin/rds is localized to
the basolateral MDCK plasma membrane, and oriented with the N-terminal epitope tag and
the C terminus on the extracellular surface.50 MDCK cells expressing human peripherin/rds
are grown to confluence in Dulbecco's modified Eagle's medium (DMEM), supplemented
with 10% fetal bovine calf serum, and isolated by scraping. The cells cannot be harvested
with trypsin, since trypsinolysis hydrolyzes the fusogenic domain of peripherin/rds. The
cells are resuspended in 145 mM NaCl, 5 mM KC1, 10 mM HEPES, pH 7.4. Fusion between
whole MDCK cells and R18–PM is measured as described above. On the addition of ROS
R18–PM to peripherin/rds-expressing MDCK cells at 37° an increase in R18 fluorescence
was observed. The initial rate of fusion under these conditions is 0.35 ± 0.040
ΔF(fluorescence)/sec. Fusion between R18–PM and peripherin/rds-expressing cells is
inhibited by the addition of 1.0 mM EGTA and by trypsinolysis of the MDCK cell plasma
membranes. Fusion is not detected with R18–PM and MDCK cells containing no peripherin/
rds. The R18 fluorescence profile seen in these assays is qualitatively similar to that shown
in Fig. 2, with a lag time of 60–90 sec.
Resonance Energy Transfer-Based Lipid Mixing Assay
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The R18 dequenching assay described above requires large quantities of MDCK cells and
may not be usable if fewer cells are available. An alternative technique requiring less
material and relying on resonance energy transfer (RET) may be used. Detection of lipid
mixing by RET requires that two membrane preparations be labeled with a fluorescent probe
at non-self-quenching concentrations. In the RET assay, pairs of fluorophores are used in
which one fluorophore, designated the energy donor, has an emission band that overlaps
with the excitation band of the second fluorophore, called the energy acceptor.51,52 When
these two fluorophores are in close proximity, as would occur in membrane bilayers on
fusion and lipid mixing, there is a transfer of the excited state energy from a donor to an
acceptor.53 Thus the acceptor fluorophore fluoresces as though it has been excited directly.
A large number of lipid probes satisfies the criteria for efficient energy transfer, and they are
called energy transfer couples.18 RET between two fluorophores has a number of
advantages51–53 when compared with the R18 lipid mixing assay for use in the MDCK cell
system: (1) The RET method is extremely sensitive, requiring only small quantities of target
membrane since the ratio of the two membranes undergoing fusion is equal; and (2) RET
assays are adapted to be performed in 96-well plates, using a fluorescence plate reader in a
total fusion reaction volume of 200 μl.54
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Two approaches have been described in using RET techniques. In the first, a single
membrane species is labeled with two fluorophores55; in the second, the fluorophores are
incorporated into two separate membrane species and fusion is detected as an increase in
fluorescence intensity of the acceptor fluorophore.54,56 In the MDCK cell system we have
employed the latter approach, using R18–PM and F18-labeled MDCK cell plasma
membranes, with a fluorescence plate reader at room temperature.54,56
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Labeling of MDCK Cells and Rod Outer Segment Plasma Membrane with Fluorescent
Membrane Probes
Purified ROS plasma membrane vesicles are labeled with R18 exactly as described above,
with the exception that the concentration of R18 incorporated is equal to 0.8 to 1.0% relative
to the membrane phospholipid. Unincorporated R18 is removed by chromatography on a
Sephadex G-75 column (total volume of the column, 1–2 ml).
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The stably transfected MDCK cells expressing human peripherin/rds are grown to
confluence and isolated by scraping. The cells are resuspended in 145 mM NaCl, 5 mM
KC1, 10 mM HEPES, pH 7.4, and labeled with 5-(N-octadecanoyl)aminofluorescein (F18),
following the same protocol as described above for R18-labeled plasma membrane. The F18
is added at 0.80–1.0 mol% relative to phospholipid in the MDCK cells. Routinely,
phospholipid phosphate24,25 is determined for each experiment and correlated to cell
number. The F18 is removed by chromatography on a Sephadex G-75 column (total volume
of the column, 1–2 ml).
R18–F18 Fusion Assay
Fusion between R18-labeled plasma membrane and F18-labeled MDCK cells is measured on
a Perkin-Elmer LS 50B spectrofluorimeter equipped with a fluorescence plate reader (model
L225 0137). Fusion is initiated by the addition of R18–PM to F18-labeled MDCK cells
present in the 96-well plates. The change in fluorescence intensity is measured continuously
for 2–10 min with λex 470 nm (F18 excitation) and at λem 524 nm (emission wavelength F18)
and λem 592 nm (emission wavelength R18). The fluorescence intensity obtained with
double-labeled plasma membrane is taken as maximal fusion. The extent of fusion (R) is
calculated as shown in Eq. (3)54:
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(3)

where I524 and I592 are the fluorescence intensities at 524 and 592 nm, respectively. The
subscripts c and t represent the initial time point and any time thereafter, respectively. On
fusion, fluorescence intensity increases at 592 nm and decreases at 524 nm, with the λex of
470 nm. To confirm that resonance energy transfer is occurring the emission scan of R18
from 500 to 680 nm is recorded. This assay may be performed on a larger scale in a
thermostatted cuvette or on coverslips.56
Advantages of MDCK Cell Line
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Peripherin/rds expressed in COS-1 cells is localized to the intracellular membranes and is
abnormally glycosylated.57 For studying fusion processes the MDCK cell line has some
important advantages over COS-1 cells: (1) In MDCK cells, peripherin/rds is also expressed
on the plasma membrane surface, thus allowing whole cells to be used in fusion assays and
easier manipulation of the membranes; (2) MDCK cells are stably transfected with human
peripherin/rds, allowing a direct correlation between the fusion-promoting activity of
peripherin/rds and human peripherin/rds disease-linked mutations; and (3) the human
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peripherin/rds expressed in MDCK cells is glycosylated and forms dimers as occurs in
native photoreceptors.50
Pitfalls of Expression Systems
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COS-1 and MDCK cells allow production of large quantities of peripherin/rds and
peripherin/rds mutants for recombination and subsequent fusion studies. In addition to the
commonly encountered shortcomings of cell expression systems, localization of
peripherin/rds to the intracellular membranes of COS-1 cells may result in artifactual
characterization of peripherin/rds-mediated fusion processes owing to the presence of
endogenous proteins involved in other fusion processes. For example, in COS-1 cells
peripherin/rds is localized to the intracellular membranes, which also contain a family of
intracellular fusion proteins58,59 that may inhibit or enhance peripherin/rds-mediated fusion.
In lieu of another expression system, such shortcomings can be overcome by characterizing
in detail the specificity of the fusion pathway. Although the overexpression of the fusion
protein may be essential for the isolation of large quantities of protein, membrane fusion
processes dependent on this protein may actually be inhibited by excessive amounts of
expressed protein. This possibility becomes more likely if a specific oligomeric form of the
protein is required for fusion competency.
Pitfalls of Resonance Energy Transfer Assays
To identify and exclude extensive membrane aggregation as a contributor to energy transfer,
EGTA or EDTA, known to decrease peripherin/rds-promoted vesicle aggregation, would
selectively decrease RET efficiency due to aggregation. In pure liposome preparations,
changes in the behavior of the membrane lipids may alter the quantum efficiency of various
fluorophores, with changes in fluorescence observed due to factors other than fusion.60
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Analysis of Individual Steps Contributing to Membrane Fusion
Once a region of a candidate fusion protein has been shown to promote fusion, the ability of
this region to mediate the individual steps in fusion can be evaluated, taking into
consideration the four steps of membrane fusion41: (1) aggregation of the fusing
membranes, (2) close approach of the lipid bilayers, (3) destabilization of the membrane
bilayer at the point of fusion (two bilayers that are closely opposed may not necessarily
fuse), and (4) mixing of the components of the lipid bilayer and of the aqueous contents, to
form a new structure. The protocols below describe how two mechanistic criteria necessary
for fusion, membrane aggregation and destabilization,61 were met for PP-5.
Membrane Aggregation–Adhesion

Author Manuscript

The Ca2+-dependent aggregation of SUVs or LUVs can be monitored continuously as a
change in absorbance at 380 nm in a Perkin-Elmer 2.0 UV/Vis spectrometer or equivalent
equipped with a thermostatted cuvette holder. As the vesicles aggregate and become larger
an increase in scattered light is detected as a change in absorbance, recorded every 0.1 min
for 10 min.23 The SUVs are composed of phosphatidylcholine– phosphatidylserine–
cholesterol (PC:PS:Choi, 4:4:1; final phosphate concentration, 1.5 mM).10,13 Aggregation is
initiated with the addition of CaCl2 (final concentration, 16 μM Ca2+). Reversible
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aggregation is distinguished from fusion by the addition of 1 M EDTA to a final
concentration of 33 mM and the absorbance is monitored for an additional 3 min. To
determine the effect of individual peptides on aggregation, the vesicles are preincubated
with peptide for 10 min at the indicated temperatures prior to the addition of calcium. The
kinetic parameters of membrane adhesion can be directly calculated from the fluorescence
data obtained in the R18 lipid mixing experiments, assuming a mass action kinetic model.62
Membrane Bilayer Destabilization
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Membrane bilayer destabilization can be inferred fluorimetrically with the fluorescent dye
3,3′-diethylthiodicarbocyanine iodide (diS-C2-5; Molecular Probes) as a collapse in a
valinomycin-induced diffusion potential in model membranes.61,63 SUVs composed of
PC:PS: Choi in a 4:4:1 molar ratio are prepared by probe sonication in the presence of K+containing buffer (50 mM K2S04, 10 mM HEPES–SO4, pH 6.8).38 An aliquot of the SUVs
(phospholipid concentration, 36 nmol) is added to 10 ml of isotonic buffer (50 mM
Na2S04,10 mM HEPES-SO4, pH 6.8) containing 10 μl of the fluorescent probe diS-C2-5
(stock, 1 mM) and incubated at 37° until a stable baseline fluorescence is established. The
addition of valinomycin to a final concentration of 10−7 M selectively permeabilizes the
vesicles to K+, creating a negative diffusion potential inside the vesicles and resulting in the
quenching of the fluorescence of the dye. Peptides from a 1-mg/ml stock in either distilled
H20 or K+-free buffer are added in 25-, 75-, or 100-μl aliquots. Fluorescence is recorded at
λex 620 nm and λem 670 nm for 90 min after the addition of the various peptides. An
increase in fluorescence intensity on the addition of peptides is indicative of a dissipation of
the diffusion potential due to peptide-induced destabilization. To quantitate the total
fluorescence recovered, fluorescence is monitored before the addition of valinomycin, after
the addition of valinomycin, and after the addition of the desired peptide. The percent
fluorescence recovery is calculated61 as shown in Eq. (4):

(4)

It is the fluorescence after the addition of the peptide, at time t, I0 is fluorescence after the
addition of valinomycin, and If is the fluorescence intensity prior to the addition of
valinomycin. Mellitin (final concentration, 9.0 μg/ml) is added to confirm that the increase
in fluorescence observed is due to a collapse in the diffusion potential. Mellitin should
dissipate the valinomycin-induced diffusion potential even after the addition of those
peptides that have no destabilizing effect.
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Membrane destabilization is inferred from the fluorescence experiments described above.
Changes in bilayer structure can be measured directly using 31 P NMR64–66 and freeze–
fracture electron microscopy.67

Conclusions
This chapter has summarized the technical advantages of fluorescence-based fusion assays
as applied to retinal rod cells and shown how these assays led to the identification of
peripherin/rds as a photoreceptor-specific fusion protein. It is important to note an added

Methods Enzymol. Author manuscript; available in PMC 2016 January 29.

Boesze-Battaglia

Page 14

Author Manuscript

benefit of this approach, namely that the data obtained can be readily analyzed in the
framework of a mass action kinetic model for fusion.68,69 Such a model depicts the overall
fusion reaction as consisting of two distinct steps: a second-order aggregation reaction and
the actual fusion event, which is first order. Spontaneous disk–plasma membrane fusion in
the ROS11 has been shown to conform to such a model. Therefore, by using a variety of
experimental conditions the rate constants of the aggregation step and fusion can be
calculated, thereby providing greater understanding of the molecular mechanism of fusion in
the ROS.
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Fig. 1.

Membrane fusion between R18–PM and ROS disk membranes. A representative tracing of
the change in fluorescence observed with the R18 lipid mixing assay, at 37°, is shown. (a)
Fusion is initiated with the simultaneous addition of R18–PM and calcium ([Ca2+]free = 45
mM) to the disk membranes, (b) The addition of Triton X-100. [Reprinted with permission
from K. Boesze-Battaglia, A. D. Albert, and P. L. Yeagle, Biochemistry 31, 3733 (1992);
American Chemical Society.]
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Fig. 2.

Membrane fusion between R18–PM and peripherin/rds recombinants. A representative
tracing of the increase in fluorescence intensity of R18 at 592 nm over time (minutes) on the
addition of R18–PM (at 15 sec) to peripherin/rds recombinants is shown at 30 and 37°. The
horizontal solid lines indicate the lag times. The initial rate of fusion is calculated from the
slope of the change in fluorescence intensity after the lag time indicated. [Reprinted with
permission from K. Boesze-Battaglia, O. P. Lamba, A. Napoli, S. Sinha, and Y. Guo,
Biochemistry 37, 9477 (1998); American Chemical Society.]
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Fig. 3.

Membrane fusion detected by aqueous contents mixing of ANTS- and DPX-containing
vesicles. Shown is a representative tracing of the decrease in fluorescence at 510 nm over
time (seconds) as the pH of the fusion mixture (ANTS vesicles and DPX vesicles) is
lowered with 2 M sodium acetate (a) at 37°.
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Table I

Comparison of R18-Labeled Plasma Membrane Fusion with Various Target Membranesa
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Target membrane

Addition
Ca2+

Lag time (sec)

IRF (%) = ΔF/time

Disks

10 μM

<20

2.9 ± 0.04

Rim-specific vesicles

10 μM Ca2+

20–50

0.26 ± 0.02

Peripherin/rds LUVs

10 μM Ca2+

120

0.30 ± 0.03

a

Fusion of R18–PMs with disk membranes,12 isolated rim-specific vesicles, and peripherin/rds recombinant LUVs23 at 37°. The initial rate of

fusion is given as the percent change in fluorescence intensity per unit time (minutes with disk membranes and seconds with rim-specific vesicles
and peripherin/rds LUVs).
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V-P-E-T-W-K-A-F-L-E-S-V-K-K-L

S-V-K-K-L-G-K-G-N-Q-V-E-A

Amino acid sequence

H2N-308-------311--------315--------------321-----------------------------331-----------------------------------------------345-COOH

W-K-A-F-L

PP-7

Residue No.

L-K-S-V-P-E-T-W-K-A-F-L

PP-6

PP-5

PP-4

PP-3

Left to right.

a
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Peptide
V-E-A-E-G-E-D-A-G-Q-A-P-A-A-G
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Aligned Amino Acid Sequence of Synthetic C-Terminal Peripherin/rds Ppetidesa
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